Evotec and Lilly to collaborate in metabolic diseases

Unter the collaboration, Evotec will use its extensive patient database in kidney disease to identify and validate promising targets for new therapeutic approaches. Based on targets identified by Lilly or Evotec, Evotec will explore potential drug candidates for the treatment of diabetes and chronic kidney disease. Lilly is entitled to select up to five programmes originating from this partnership for commercialisation.

The collaboration is initially for three years. In addition to an undisclosed upfront payment, Evotec is eligible to receive success-based development, regulatory and commercialisation milestone payments of up to US$180m per programme, as well as tiered royalties on net sales of any products resulting from the collaboration. In total, the potential total value of the collaboration is up to US$1 billion.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Over several years, Evotec has systematically built a proprietary patient database for metabolic and renal diseases through multi-omics analyses of samples from patient biobanks. Combined with Evotec’s omics-based multimodal drug discovery and development platform, this patient-derived data provides high quality drug candidates for our partners. We are proud to work with Lilly as one of the leaders in diabetes and kidney disease